Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
CVRx, Inc. CVRX
$12.20
+$0.37 (3.04%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
250784779.00000000
-
week52high
19.94
-
week52low
4.96
-
Revenue
22469000
-
P/E TTM
-6
-
Beta
0.00000000
-
EPS
-2.25000000
-
Last Dividend
0.00000000
-
Next Earnings Date
27 апр 2023 г. в 21:00
Описание компании
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Craig-Hallum | Buy | 18 июл 2022 г. | |
| William Blair | Outperform | 26 июл 2021 г. | |
| Piper Sandler | Overweight | 26 июл 2021 г. | |
| JP Morgan | Overweight | 26 июл 2021 г. | |
| Canaccord Genuity | Buy | 26 июл 2021 г. | |
| Piper Sandler | Overweight | Overweight | 02 ноя 2022 г. |
| JP Morgan | Overweight | Overweight | 27 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| OASHEIM JARED | A | 70000 | 70000 | 18 янв 2023 г. |
| Palmer Craig E. | A | 40000 | 40000 | 18 янв 2023 г. |
| Galle Liz | A | 26000 | 26000 | 18 янв 2023 г. |
| Yared Nadim | A | 200000 | 200000 | 18 янв 2023 г. |
| VERRASTRO PAUL | A | 45000 | 45000 | 18 янв 2023 г. |
| Yared Nadim | D | 20255 | 7080 | 11 янв 2023 г. |
| Hykes Kevin | A | 21776 | 21776 | 21 дек 2022 г. |
| Hykes Kevin | A | 5246 | 5246 | 21 дек 2022 г. |
| VERRASTRO PAUL | D | 0 | 4400 | 30 ноя 2022 г. |
| VERRASTRO PAUL | D | 84556 | 9000 | 28 ноя 2022 г. |
Новостная лента
CVRx, Inc. (CVRX) Q4 2022 Earnings Call Transcript
Seeking Alpha
26 янв 2023 г. в 21:10
CVRx, Inc. (NASDAQ:CVRX ) Q4 2022 Earnings Conference Call January 26, 2023 5:30 PM ET Company Participants Mike Vallie - Westwicke, ICR Company Nadim Yared - President and Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Matthew O'Brien - Piper Sandler Margaret Kaczor - William Blair William Plovanic - Canaccord Genuity Alex Nowak - Craig-Hallum Operator Good day and welcome to the CVRx Q4 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
26 янв 2023 г. в 19:33
CVRx (CVRX) delivered earnings and revenue surprises of 7.27% and 5.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
CVRx to Report Fourth Quarter and Fiscal Year 2022 Financial and Operating Results and Host Conference Call on January 26, 2023
GlobeNewsWire
12 янв 2023 г. в 17:30
MINNEAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release fourth quarter and full year 2022 financial and operating results after market close on Thursday, January 26, 2023. The Company will host a conference call to review its results at 5:30 p.m. Eastern Time the same day.
CVRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
28 дек 2022 г. в 08:30
MINNEAPOLIS, Dec. 28, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023. The Company is scheduled to present at the conference at 3:45 pm Pacific Time.
CVRx: Barostim Accelerating, Upside Targets Forming (Technical Analysis)
Seeking Alpha
05 дек 2022 г. в 15:09
Q3 revenues came in 82% higher YoY to $6.2mm, with the heart failure business growing to $4.9mm for the quarter. Market data is improving, along with more visibility on macro variables and less price volatility in equity markets as a result.